On February 28, 2017 Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, reported that the Company received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming the methods for generating a radioimmunoconjugate comprised of actinium-225, an alpha emitting radioisotope, conjugated to monoclonal antibodies (Press release, Actinium Pharmaceuticals, FEB 28, 2017, View Source [SID1234517883]). Schedule your 30 min Free 1stOncology Demo! Actinium-225 is the radioisotope used in Actinium’s Actimab-A, a drug candidate in a Phase 2 clinical trial for patients newly diagnosed with acute myeloid leukemia (AML) who are over the age of 60; Actimab-M, a drug candidate in a Phase 1 trial for patients with relapsed or refractory multiple myeloma (MM); and the Company’s alpha particle immunotherapy technology platform. Actinium currently has 61 issued and pending patents that are owned or licensed relating to isotope production methods, drug preparation methods and the Company’s platform technology. This patent is expected to expire in July of 2030.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sandesh Seth, Actinium’s Executive Chairman said, "Actinium-225 is an excellent isotope for medical applications given its half-life, potency, safety profile and relatively ease of handling. As a result, it is an important aspect of Actinium’s Actimab-A and Actimab-M programs and alpha particle immunotherapy technology (APIT) platform. We welcome this addition to our intellectual property portfolio, which now consists of more than 60 patents. We will continue to invest in our intellectual property portfolio to further enhance our position in the use of alpha particles to enhance outcomes for patients."
The claims of this patent are for a method for producing actinium-225 radioconjugates, the method comprising the steps of: a) conjugating a chelating agents to a biological molecule in a conjugations reaction mixture to generate a conjugated biological molecule, b) purifying the reaction mixture so as to remove unconjugated chelating agents, and c) chelating one or more actinium-225 radionuclides with the conjugated biological molecule in a chelation reaction mixture to generate an actinium-225 radioconjugate.